VRDN

Viridian Therapeutics, Inc.

14.52 USD
+0.05 (+0.35%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Viridian Therapeutics, Inc. stock is up 19.21% since 30 days ago. The next earnings date is Aug 6, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 7 July’s closed higher than June. In the last 5 Unusual Options Trades, there were 1 PUT, 4 CALLs.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
11 Jun 15:28 17 Jan, 2025 12.50 PUT 68 2
11 Jun 15:28 17 Jan, 2025 12.50 CALL 68 0
16 Jul 16:02 20 Sep, 2024 17.50 CALL 500 1030
16 Jul 16:03 20 Sep, 2024 17.50 CALL 1468 1030
16 Jul 17:03 17 Jan, 2025 12.50 CALL 42 222

About Viridian Therapeutics, Inc.

Viridian Therapeutics, Inc. develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED) The company was founded in 2006 and is headquartered in Waltham, Massachusetts.